Phase III Clinical Trial of DengiAll® by ICMR and Panacea Biotec - Completion of enrollment of study participants

Panacea Biotec Limited has announced that the enrollment of study participants in context of DengiAll® Phase-III clinical trial has been completed (i.e., 10,335 study participants).

The Company shall continue to monitor each participant, post administration of the Investigational Medicinal Product (i.e., vaccine or Placebo), for a period of two years to examine the efficacy and immunogenicity of the vaccine.

DengiAll® will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027.

Shares of Panacea Biotec Limited was last trading in BSE at Rs. 383.70 as compared to the previous close of Rs. 365.90. The total number of shares traded during the day was 19116 in over 449 trades.

The stock hit an intraday high of Rs. 387.30 and intraday low of 364.00. The net turnover during the day was Rs. 7203203.00.

Source : Equity Bulls

Keywords

PanaceaBiotec INE922B01023 Biotechnology Phase3 ClinicalTrial DengiAll